The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

David S. Hong, MD, discusses data examining the use of sotorasib (Lumakras) and adagrasib in colorectal cancer.

Tapan M. Kadia, MD, discusses what makes uproleselan unique from other agents under investigation in acute myeloid leukemia and sheds light on the many research efforts dedicated to further exploring its use in this disease.

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

Srdan Verstovsek, MD, PhD, discusses the efficacy of momelotinib in myelofibrosis.

Tapan M. Kadia, MD, discusses the utilization of uproleselan with chemotherapy in relapsed/refractory acute myeloid leukemia.

James P. Allison, PhD, a Nobel Laureate and Giants of Cancer Care® award winner, will head up the new James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Hussein A. Tawbi, MD, PhD, discusses the FDA approval of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Debu Tripathy, MD, discusses the emergence of genomics research in breast cancer.

Jason R. Westin, MD, director, discusses the utilization of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

The MEK inhibitor trametinib reduced the risk of disease progression or death by 52% compared with current standard-of-care therapies in patients with relapsed or persistent low-grade serous ovarian carcinoma, making it the potential new SOC for this patient population.

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer.

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Jan A. Burger, MD, PhD, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Debasish Tripathy, MD, provides perspective on some of the key data sets that were presented and published in 2021 in HER2-positive breast cancer.

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Induction treatment with ibrutinib and rituximab was safe and active in patients with mantle cell lymphoma aged 65 years or younger, allowing for fewer cycles of subsequent chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone thereby reducing toxicity.